-
PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma
2026-09-12
This Cancer Letters study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-regulated RNA splicing, with downstream effects on epitranscriptomic control and glutamine metabolism. Its integrated genetic, transcriptomic, metabolic, and in vivo data identify GLS regulation as a mechanistic consequence of PRMT5 inhibition and provide a rationale for testing downstream glutaminolysis interventions.
-
Inducing Embryonic Dormancy Through mTOR Inhibition
2026-09-11
This Nature Protocols article presents noninvasive in vitro procedures for placing mouse blastocysts, human blastoids, and pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. The workflow replaces laborious surgery-based models with scalable culture systems for studying dormancy, developmental competence, and the molecular control of early embryogenesis.
-
MRSA Extracellular Vesicles Drive OSCC via IL-8
2026-09-11
This study identifies methicillin-resistant Staphylococcus aureus extracellular vesicles as active drivers of oral squamous cell carcinoma progression, rather than passive markers of infection. By combining EV comparisons, pathway inhibition, IL-8 loss-of-function, and CXCR1 blockade, the work connects bacterial resistance biology to an ERK/c-Jun–IL-8–CXCR1–JAK/STAT5A proliferative circuit.
-
D-Luciferin: A Mechanistic Lens on Tumor Biology
2026-09-10
D-Luciferin potassium salt enables longitudinal in vivo bioluminescence imaging, but its greatest value lies in connecting tumor burden measurements with mechanistic questions. This article explains how to interpret luciferase signals alongside the BCL6–ESM1–CD4+ T-cell axis described in recent hepatocellular carcinoma research.
-
Site-Specific IL-11 PEGylation in Pulmonary Fibrosis
2026-09-10
Wang and colleagues engineered receptor-biased IL-11 variants by placing PEG at the GP130-binding interface, reducing GP130 engagement while largely preserving IL-11Rα binding. In bleomycin-induced pulmonary fibrosis, the optimized conjugates extended IL-11 exposure and reduced extracellular matrix deposition, providing a selective cytokine-engineering strategy for fibrotic disease research.
-
Cefotaxime for AMR Transmission Workflows
2026-09-09
Cefotaxime provides a practical phenotypic probe for connecting beta-lactam activity with plasmid transmission, carbapenemase genes, and bacterial infection model performance. This guide combines a reproducible susceptibility workflow with troubleshooting strategies that help distinguish compound behavior from resistance-genotype effects.
-
Lypressin Acetate: Receptor Biology to Translation
2026-09-09
Lypressin acetate is a lysine vasopressin analog whose receptor breadth, short systemic half-life, and quantified bioactivity create both opportunities and interpretive challenges. This evidence-weighted guide connects molecular pharmacology with assay design, diabetes insipidus research, vasoconstriction research, and preliminary antiviral hypotheses.
-
SMYD2, miR-125b, and Drug Resistance in RCC
2026-09-08
The reference study identifies SMYD2 as both a prognostic marker and a functional driver of clear cell renal cell carcinoma, linking epigenetic regulation of miR-125b and DKK3 to tumor behavior. Its combination of patient profiling, chromatin assays, miRNA analysis, xenografts, and multidrug-response testing provides a mechanistic framework for understanding P-glycoprotein-associated resistance in RCC.
-
Mavorixafor in WHIM Syndrome: Phase 3 Evidence
2026-09-08
The Blood commentary on Badolato et al. highlights a placebo-controlled phase 3 evaluation of oral mavorixafor, a CXCR4 antagonist, in patients with WHIM syndrome. The study showed sustained increases in neutrophil and lymphocyte availability and fewer infections, while also identifying important questions about long-term safety, immune recovery, and disease-specific outcomes.
-
Realgar, OTC, and Astrocyte Glycolysis
2026-09-07
A 2025 Advanced Science study identifies a liver–brain mechanism linking realgar-derived arsenic, hepatic OTC inhibition, ornithine accumulation, and ZBTB7A-mediated suppression of astrocyte glycolysis. Its integrated animal, cell, transcriptomic, metabolomic, behavioral, and histopathological analyses provide a mechanistic framework for studying arsenic-associated CNS injury and related amino acid metabolism.
-
Deferasirox Fe3+ Chelate Research Workflows
2026-09-07
Build reproducible iron-speciation, uptake, and toxicity assays around a defined ferric chelate rather than treating it as interchangeable with free deferasirox. This guide combines practical DMSO handling, controls, comparative assay design, and clinically grounded interpretation for iron overload treatment research.
-
L-Alanyl-L-Glutamine: Practical GI Assay Guide
2026-09-05
L-Alanyl-L-Glutamine provides a defined, water-soluble dipeptide format for glutamine delivery in aqueous gastrointestinal, nutritional, and barrier-assay workflows. It is suitable for controlled aqueous studies but not for DMSO- or ethanol-based formulations or long-term storage of prepared solutions.
-
PRMT5, Splicing, and Metabolism in MYCN Neuroblastoma
2026-09-04
This Cancer Letters study shows that MYCN-amplified neuroblastoma depends on PRMT5-mediated control of RNA splicing, epitranscriptomic regulation, and glutamine metabolism. Its integrated transcriptomic, metabolic, molecular, and in vivo analyses identify GLS regulation as a mechanistic consequence of spliceosomal stress rather than an isolated metabolic phenotype.
-
Vasopressin Analogues: Innovation and Evidence
2026-09-04
Glavaš and colleagues review how vasopressin structure, receptor pharmacology, and peptide engineering have produced analogues with more selective antidiuretic, vasoconstrictive, or longer-acting profiles. The article is especially useful for interpreting lypressin, desmopressin, and terlipressin as distinct pharmacological tools while identifying the translational limits of peptide delivery and emerging antiviral hypotheses.
-
7-Ethyl-10-hydroxycamptothecin Research Workflows
2026-09-03
Build more informative cancer assays with 7-Ethyl-10-hydroxycamptothecin (SN-38), combining topoisomerase I stress, apoptosis, cell-cycle profiling, and FUBP1/FUSE readouts. This practical guide covers solvent handling, time-course design, metastatic colon cancer models, and troubleshooting for advanced oncology research.